Conejo Valley-based Acelyrin, a clinical, pre-revenue biotechnology company, reported its financial results for the full year 2023 on March 28. According to the March 28 report, the company’s net loss for the full year ended Dec. 31 was $381.6 million, compared to $64.8 million for 2022. The company primarily saw expenses increase in research and